Year-end Sale % OFF 
Abstract
Abstract Surgery is the only curative treatment modality in rectal cancer. However, in patients with locally advanced T3 or T4 tumors with or without nodal involvement, the risk of local and systemic recurrence is high. Adjuvant (postoperative) therapy aims to reduce the risks of local as well as distant recurrence and decrease cancer-related mortality. Postoperative chemoradiotherapy has been the gold standard. However, the adjuvant treatment of rectal cancer is continuing to evolve due to the greater use of surgical techniques such as total mesorectal excision as well as neoadjuvant (preoperative) radiotherapy or chemoradiotherapy and new systemic agents. This review summarizes the various types of adjuvant and neoadjuvant therapies, their current status, and the morbidity of these treatment modalities. Copyright 2002, Elsevier Science (USA). All rights reserved.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
